Author: Bai Xu
Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.17, Iss.7, 2007-07, pp. : 791-797
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Since their initial discovery, azetidinones have been extensively studied as potent cholesterol absorption inhibitors. Ezetimibe is the first-in-class and only member in the clinics either as a monotherapy or in combination with statins for treatment of hypercholesterolemia. The recent identification of Niemann–Pick C1-like 1 protein in the brush border membrane of the small intestine as a possible molecular target has opened the door for the design and synthesis of new anticholesterol drugs. This article reviews the important literature and patents on cholesterol absorption inhibitors.
Related content
Cholesterol Absorption Inhibitors for the Treatment of Hypercholesterolaemia
Drugs, Vol. 62, Iss. 16, 2002-01 ,pp. :
Virtual Screening for Cholesterol Absorption Inhibitors
Medicinal Chemistry, Vol. 11, Iss. 1, 2015-01 ,pp. :